BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 23776131)

  • 1. CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer.
    Cepeda D; Ng HF; Sharifi HR; Mahmoudi S; Cerrato VS; Fredlund E; Magnusson K; Nilsson H; Malyukova A; Rantala J; Klevebring D; Viñals F; Bhaskaran N; Zakaria SM; Rahmanto AS; Grotegut S; Nielsen ML; Szigyarto CA; Sun D; Lerner M; Navani S; Widschwendter M; Uhlén M; Jirström K; Pontén F; Wohlschlegel J; Grandér D; Spruck C; Larsson LG; Sangfelt O
    EMBO Mol Med; 2013 Jul; 5(7):1067-86. PubMed ID: 23776131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SCF
    Cai L; Liu L; Li L; Jia L
    Cell Signal; 2020 Jan; 65():109440. PubMed ID: 31678254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression.
    O'Hagan RC; Ohh M; David G; de Alboran IM; Alt FW; Kaelin WG; DePinho RA
    Genes Dev; 2000 Sep; 14(17):2185-91. PubMed ID: 10970882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
    Kang J; Sergio CM; Sutherland RL; Musgrove EA
    BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.
    Inuzuka H; Shaik S; Onoyama I; Gao D; Tseng A; Maser RS; Zhai B; Wan L; Gutierrez A; Lau AW; Xiao Y; Christie AL; Aster J; Settleman J; Gygi SP; Kung AL; Look T; Nakayama KI; DePinho RA; Wei W
    Nature; 2011 Mar; 471(7336):104-9. PubMed ID: 21368833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of GATA-binding protein 2 levels via ubiquitin-dependent degradation by Fbw7: involvement of cyclin B-cyclin-dependent kinase 1-mediated phosphorylation of THR176 in GATA-binding protein 2.
    Nakajima T; Kitagawa K; Ohhata T; Sakai S; Uchida C; Shibata K; Minegishi N; Yumimoto K; Nakayama KI; Masumoto K; Katou F; Niida H; Kitagawa M
    J Biol Chem; 2015 Apr; 290(16):10368-81. PubMed ID: 25670854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An SCF
    Gorrepati KDD; He W; Lupse B; Yuan T; Maedler K; Ardestani A
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FBXO28 promotes proliferation, invasion, and metastasis of pancreatic cancer cells through regulation of SMARCC2 ubiquitination.
    Liu S; Liu P; Zhu C; Yang R; He Z; Li Y; Li Y; Fei X; Hou J; Wang X; Pan Y
    Aging (Albany NY); 2023 Jun; 15(12):5381-5398. PubMed ID: 37348029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysine-52 stabilizes the MYC oncoprotein through an SCF
    De Melo J; Kim SS; Lourenco C; Penn LZ
    Oncogene; 2017 Dec; 36(49):6815-6822. PubMed ID: 28806398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ubiquitin-specific protease USP28 is required for MYC stability.
    Popov N; Wanzel M; Madiredjo M; Zhang D; Beijersbergen R; Bernards R; Moll R; Elledge SJ; Eilers M
    Nat Cell Biol; 2007 Jul; 9(7):765-74. PubMed ID: 17558397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The E3 ubiquitin ligase SCF
    Chen F; Zhang C; Wu H; Ma Y; Luo X; Gong X; Jiang F; Gui Y; Zhang H; Lu F
    J Biol Chem; 2017 Dec; 292(49):20100-20112. PubMed ID: 29070679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The F-box protein FBXL16 up-regulates the stability of C-MYC oncoprotein by antagonizing the activity of the F-box protein FBW7.
    Morel M; Shah KN; Long W
    J Biol Chem; 2020 Jun; 295(23):7970-7980. PubMed ID: 32345600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FBXO28 suppresses liver cancer invasion and metastasis by promoting PKA-dependent SNAI2 degradation.
    Qiao X; Lin J; Shen J; Chen Y; Zheng L; Ren H; Zhao X; Yang H; Li P; Wang Z
    Oncogene; 2023 Sep; 42(39):2878-2891. PubMed ID: 37596321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity.
    Mei Z; Zhang D; Hu B; Wang J; Shen X; Xiao W
    J Biol Chem; 2015 Jun; 290(26):16202-14. PubMed ID: 25944903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E2F1 proteolysis via SCF-cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition.
    Burdova K; Yang H; Faedda R; Hume S; Chauhan J; Ebner D; Kessler BM; Vendrell I; Drewry DH; Wells CI; Hatch SB; Dianov GL; Buffa FM; D'Angiolella V
    EMBO J; 2019 Oct; 38(20):e101443. PubMed ID: 31424118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ubiquitin ligase SCF
    Song N; Cao C; Tang Y; Bi L; Jiang Y; Zhou Y; Song X; Liu L; Ge W
    J Cell Physiol; 2018 Mar; 233(3):2366-2377. PubMed ID: 28722108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex.
    Lin DI; Barbash O; Kumar KG; Weber JD; Harper JW; Klein-Szanto AJ; Rustgi A; Fuchs SY; Diehl JA
    Mol Cell; 2006 Nov; 24(3):355-66. PubMed ID: 17081987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sublytic C5b-9 induces proliferation of glomerular mesangial cells via ERK5/MZF1/RGC-32 axis activated by FBXO28-TRAF6 complex.
    Yu T; Wang L; Zhao C; Qian B; Yao C; He F; Zhu Y; Cai M; Li M; Zhao D; Zhang J; Wang Y; Qiu W
    J Cell Mol Med; 2019 Aug; 23(8):5654-5671. PubMed ID: 31184423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of neddylation and deneddylation of cullin1 in SCFSkp2 ubiquitin ligase by F-box protein and substrate.
    Bornstein G; Ganoth D; Hershko A
    Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11515-20. PubMed ID: 16861300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SCF
    Sugiyama S; Yumimoto K; Inoue I; Nakayama KI
    Genes Cells; 2019 May; 24(5):354-365. PubMed ID: 30838725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.